摘要
目的:探讨血清HE4、CA125和CA199联检对卵巢癌的诊断价值。方法:收集卵巢癌患者85例和正常人60例,采用雅培ARCHITECT Plus i2000微粒子免疫化学发光分析仪对血清HE4、CA125和CA199进行测定。结果:卵巢癌组血清HE4、CA125和CA199检测结果分别为(118.62±42.34)pmol/m L、(288.3±56.2)U/m L和(123.±34.5)U/m L,与健康对照组相比差异具有统计学意义(P<0.01)。卵巢癌组血清HE4、CA125和CA199阳性率分别为69.4%、65.9%、52.9%,联合检测阳性率90.6%。结论:血清HE4、CA125和CA199联合检测可提高诊断阳性率,对早期卵巢癌的临床辅助诊断有一定价值。
Objective:To explore the diagnostic value of combined detection of serum HE4、CA125 and CA199 in ovarian cancer.Methods:85 patients with ovarian cancer and 60 cases of normal were selected.Using Abbott ARCHITECT Plus i2000 particles immune chemiluminescence analyzer measured the serum HE4,CA125 and CA199.Results:The serum HE4,CA125 and CA199 detection result of the ovarian cancer group were respectively(118.62±42.34)pmol/m L,(288.3±56.2)U/m L and(123.±34.5)U/m L.There had significant differences when compared with the healthy control group(P<0.01).The serum HE4,CA125 and CA199 positive rates of the ovarian cancer group were respectively 69.4%,65.9%,52.9%,and the positive rate of combined detection was90.6%.Conclusion:The combined detection of serum HE4,CA125 and CA199 can improve the diagnostic positive rate,and it has certain value for the clinical auxiliary diagnosis of early ovarian cancer.
出处
《中国社区医师》
2015年第22期104-105,共2页
Chinese Community Doctors
